FtsZ-IN-1 

FtsZ-IN-1 is a potent FtsZ inhibitor with quinolinium ring. FtsZ-IN-1 has stronger antibacterial activity against Gram-positive bacteria with MICs of 0.5-8 μg/mL. FtsZ-IN-1 significantly causes cell elongation of B. subtilis by enhancing FtsZ polymerization. FtsZ-IN-1 exhibits low hemolytic toxicity and low tendency to induce agent resistance. FtsZ-IN-1 has against drug-resistant bacteria activity^[1].

FtsZ^[1]

FtsZ-IN-1 (compound A3) inhibits effectively the growth of S. aureus with MICs of 0.5-1 μg/mL, and generally displays less antibacterial potency against most Gram-negative bacteria tested such as E. coli ATCC 8739 (MIC = 64 μg/mL) and P. Aeruginosa ATCC 27853 (MIC >64 μg/mL)^[1].
FtsZ-IN-1 exhibits MBCs of 4-8 μg/mL and MICs of 1-4 μg/mL against S. aureus, B. subtilis and E. faecium^[1].
FtsZ-IN-1 (0-24 μg/mL; 24 hours) inhibits the growth of S. aureus in a bacteriostatic mode at 1×, 2×, 4× MIC concentrations, and kills S. aureus at 8× MIC concentration^[1].
FtsZ-IN-1 can restore the antibacterial activity of methicillin against MRSA in a synergistic manner, with MIC of 2 μg/mL^[1].
FtsZ-IN-1 (2 μg/mL; 4 hours) can enlarge cell size of B. subtilis and inhibits bacterial cell division^[1].
FtsZ-IN-1 (0-15 μg/mL; 48 hours) exhibits IC₅₀s of 12.77 and 9.42 μg/mL in L929 and HK-2 cells^[1].
FtsZ-IN-1 (2 μg/mL) can effectively delay the induction of drug resistance^[1].
In a Hemolytic activity assay, FtsZ-IN-1 (1-64 μg/mL; 1 hour) exhibits low hemolytic toxicity in mice erythrocytes (from Kunming mice) with IC₅ of 64 μg/mL^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

FtsZ-IN-1 (1-64 μg/mL; 1 hour) exhibits low hemolytic toxicity in mice erythrocytes (from Kunming mice) with IC₅ of 64 μg/mL^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

513.46

C₂₆H₃₂IN₃

2516246-24-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhong DX, She MT, Guo XC, et al. Design and synthesis of quinolinium-based derivatives targeting FtsZ for antibacterial evaluation and mechanistic study. Eur J Med Chem. 2022;236:114360.  [Content Brief]